Heron Therapeutics | HRTX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 73.66M 9.14M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
Eisai JPY 119.54B 7.82B 2026-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.26M 34.78M 2026-03
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 83.88M 7.99M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 50.84M 7.53M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03